Category: Mikhail Blagosklonny
Most people don’t think about cancer on a daily basis. Unless they have someone in their family or friend circle diagnosed with the disease. Researchers are trying to find ways how to cure cancer and Mikhail Blagosklonny is one of them.
Cancer And Aging Research
Have you ever heard Mikhail Blagosklonny’s name? Few people have, but in the coming years, it will change. He researches cancer as well as aging. Since receiving his M.D., Blagosklonny has been in the headlines. He publishes research in medical journals. Blagosklonny wants to find out what kind of connections there is between old age and cancer. And why older individuals are more likely to receive a cancer diagnosis.
At this point the treatment is expensive. Chemotherapy and radiotherapy can have serious side-effects. People experience nausea, pain and muscle weakness among others. The underlying goal is to find a cure to cancer. The aim is also to find a cheaper and less painful manner of treating cancer.
The cure lies in the disease itself. There is a hope to end cancer cells from duplicating and then reappearing in the patient’s body. One of the research ideas Blagosklonny talks about includes Rapamycin. He is working to prove that it can help people live longer. This way their health benefits as well because it slows down the natural aging process.
What Is Rapamycin?
This drug is known in the industry as Sirolimus. This compound has different uses. Coating stents and help people with organ transplants as well as treatment for LAM – a rare lung disease. It works by assimilating itself in human T cells and B cells. Blagosklonny argues, that aging is a growth in development that never stops. He wants to prove that Rapamycin slows the process down. This also impacts the possibility of cancer.
If this drug slows down the aging process at the cell level, it can also delay targeting the immune system. Studies so far have expressed support. Rapalogs are effective in a combination of other medication. Blagosklonny thinks that people should administer rapamycin before cancer appears. Blagosklonny says that a typical cocktail of anti-cancer medication can shorten the lifespan. He also expresses that it can make the side-effects more severe.
The research proved to be successful. The pharmaceutical industry can begin a move towards a less-intrusive treatment. For people with cancer, these are welcome news. It could also mean preventing the disease from appearing in more people, but that is yet to come. Since its discovery, rapamycin has received approval for clinical trials. Blagosklonny’s research has inspired his colleagues to look for more alternatives to rapamycin. So far a few have survived the test as well with great results. It has worked in changing the way the immune system works. It allows it to be less prone to different cancer strains. But, it is still not a complete cure as people with aggressive forms of cancer are still waiting for one.